Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday

Key Points

• Lexeo Therapeutics is set to release its Q2 2025 earnings report on August 11th, with analysts predicting an earnings per share (EPS) of ($0.61).
• In its last earnings report, Lexeo missed estimates with an EPS of ($0.99), falling short of the expected ($0.80).
• Wall Street analysts have mixed views on Lexeo, with a consensus buy rating and a price target averaging $17.17, although JPMorgan recently lowered its target from $16.00 to $10.00.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). On average, analysts expect Lexeo Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lexeo Therapeutics Trading Down 0.9%

Shares of LXEO stock traded down $0.04 on Friday, hitting $4.41. The stock had a trading volume of 39,684 shares, compared to its average volume of 661,803. The company's 50 day moving average price is $4.14 and its 200-day moving average price is $3.73. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $12.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.42 and a quick ratio of 3.42. The firm has a market capitalization of $146.48 million, a P/E ratio of -1.34 and a beta of 1.36.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC lifted its stake in Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock worth $3,718,000 after acquiring an additional 929,538 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock worth $175,000 after purchasing an additional 39,627 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Lexeo Therapeutics during the first quarter worth $85,000. Finally, Rhumbline Advisers increased its holdings in Lexeo Therapeutics by 19.8% in the first quarter. Rhumbline Advisers now owns 30,192 shares of the company's stock valued at $105,000 after buying an additional 4,995 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LXEO has been the subject of several research reports. Oppenheimer started coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They issued an "outperform" rating and a $20.00 target price for the company. HC Wainwright dropped their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, May 16th. JPMorgan Chase & Co. reduced their target price on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 30th. Finally, Chardan Capital dropped their price target on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $17.17.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.